The Sodium Channel Protein Type 2 Subunit Alpha pipeline drugs market research report outlays comprehensive information on the Sodium Channel Protein Type 2 Subunit Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sodium Channel Protein Type 2 Subunit Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, and Gastrointestinal which include the indications Post-Operative Pain, Epilepsy, and Oral Mucositis. It also reviews key players involved in Sodium Channel Protein Type 2 Subunit Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Sodium Channel Protein Type 2 Subunit Alpha pipeline targets constitutes close to 18 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 3, 3, 6, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Sodium Channel Protein Type 2 Subunit Alpha overview
SCN2A is a gene that codes for a sodium channel in the brain. The SCN2A mutation leads to overactivity of the ion channel and leads to decreased activity of the ion channel. Changes in the flow of sodium ions in the brain cause epilepsy and associated developmental differences.
For a complete picture of Sodium Channel Protein Type 2 Subunit Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
